Herantis Pharma publishes a July-September newsletter

Herantis Pharma Plc
Company release 15 Sep 2020 at 9:00 am

Herantis Pharma Plc
Press release
15 Sep 2020 at 09:00 am Eastern European Summer Time

Herantis Pharma Plc (“Herantis”) has published its newsletter for JulySep 2020. The newsletter is also attached to this press release.

Herantis’ newsletter is published every other month on the company’s web site. It is also available by email subscription.

Further information:

Julie Silber / Gabriela Urquilla

JG-IR

Tel: +46 (0)7 93 486 277 / +46 (0)72-396 72 19

Email:ir@herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland with ticker symbol “HRTIS” and Nasdaq First North Growth Market Sweden with ticker symbol “HRNTS”. Subscribe to Herantis’ news at https://herantis.com/subscribe/.

Distribution:

Main media
www.herantis.com

Attachment

Newsletter_Sep_2020_ENG.pdf

Attachment